Pharmaceutical

EMA and FDA green-light MoonLake to advance IL-17 inhibitor

The Phase III VELA programme will compare the IL-17 inhibitor sonelokimab to a placebo, enrolling 800 patients over 52 weeks.

Feb 28, 2024 - 18:00
EMA and FDA green-light MoonLake to advance IL-17 inhibitor
The Phase III VELA programme will compare the IL-17 inhibitor sonelokimab to a placebo, enrolling 800 patients over 52 weeks.
Read the original article

Tags:

Previous Article

Beyond approval: Patients pursue alternate paths to get rare disease treatments

Next Article

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space 

GC Therapeutics secures $65m to launch into off-the-she...

Sep 22, 2024

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga ...

Aug 13, 2024

Epigenetic drugs show 375% increase in Series A venture financing in 2024

Epigenetic drugs show 375% increase in Series A venture...

Sep 26, 2024